The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
These systems can carry more than one type of drug, targeting specific molecules, which helps to deliver a stronger punch to tumor tissues. Altogether, these breakthroughs point to a potential for nanoparticle-based controlled-release therapies in the fields of cancer therapy and personalized medicine.
== Philanthropy == In April 2017, Metropolis launched a scholarship and mentorship program, called "Medengage", for undergraduate and postgraduate medical students across India. In July 2017, Metropolis and the PCOS Society of India launched a Polycystic Ovarian Syndrome (PCOS) awareness campaign called "Conquer PCOS". In August 2018, Metropolis initiated an "Umbrella Handshake" campaign to create awareness about health. The company donated ₹2 million (equivalent to ₹2.9 million or US$30,000 in 2026) towards this and other social welfare initiatives. Metropolis partnered with We Foundation and Red FM, to help in public outreach and campaign awareness.
The procedure is illustrated by the synthesis of a dipeptide library using the same three amino acids as building blocks in both cycles. Each component of this library contains two amino acids arranged in different orders. The amino acids used in couplings are represented by yellow, blue and red circles in the figure. Divergent arrows show the division of solid support resin (green circles) into equal portions, vertical arrows mean coupling, and convergent arrows represent the mixing and homogenizing of the portions of the support. The figure shows that, in the two synthetic cycles, 9 dipeptides are formed. In the third and fourth cycles, 27 tripeptides and 81 tetrapeptides would form respectively. The "split-mix synthesis" has several outstanding features:
Sources: en.wikipedia.org
== History == Tom Kudirka, originally from Omaha, Nebraska, and an alumnus of Bellevue West High School, had studied business information systems and electronics before moving to Tulsa to work for Lucent Technologies as a field engineer. Thereafter, he had established multimedia companies, including one dealing with speech recognition. Because Kudirka "thought he was bored", he founded 2015 in Tulsa in May 1997. The name was said to have been chosen for an undisclosed "very significant" reason, although Kudirka later said he did not know what it meant. Kudirka recruited developers he had discovered online and had them relocate to Tulsa. The designer Zied Rieke was the first hire. Through Kudirka's connections with Ritual Entertainment and its CEO, 2015 came to develop Wages of Sin, an expansion pack for Ritual Entertainment's 1998 game Sin. It was released in February 1999. On April 3, 2000, 2015 announced the opening of its Trainwreck Studios division for budget-price games with a wider target audience. The first game therein, Laser Arena, was designed to be playable by Kudirka's three-year-old son and released in September 2000. 2015 was simultaneously working on its third game, Heavy Gear Extreme. The company grew to 15 people, requiring it to expand its office space at 8282 South Memorial Drive. The second Trainwreck Studios game, CIA Operative: Solo Missions, was released in May 2001. 2015 was reported as developing Half-Life: Hostile Takeover as an expansion for Half-Life in November 1999.
Some other researchers were more optimistic. AI pioneer Jürgen Schmidhuber did not sign the joint statement, emphasising that in 95% of all cases, AI research is about making "human lives longer and healthier and easier." While the tools that are now being used to improve lives can also be used by bad actors, "they can also be used against the bad actors." Andrew Ng also argued that "it's a mistake to fall for the doomsday hype on AI—and that regulators who do will only benefit vested interests." Yann LeCun, a Turing Award winner, disagreed with the idea that AI will subordinate humans "simply because they are smarter, let alone destroy [us]", "scoff[ing] at his peers' dystopian scenarios of supercharged misinformation and even, eventually, human extinction." In contrast, he claimed that "intelligent machines will usher in a new renaissance for humanity, a new era of enlightenment." In the early 2010s, experts argued that the risks are too distant in the future to warrant research or that humans will be valuable from the perspective of a superintelligent machine. However, after 2016, the study of current and future risks and possible solutions became a serious area of research. Some have argued that concerns about existential risks of AI could draw attention away from other AI risks.
anti-fascists persons crucial for industries those married to ethnic Czechs It is estimated that between 700,000 and 800,000 Germans were affected by "wild" expulsions between May and August 1945. The expulsions were encouraged by Czechoslovak politicians and were generally carried out by the order of local authorities, mostly by groups of armed volunteers. However, in some cases it was initiated or pursued by assistance of the regular army. The expulsion according to the Potsdam Conference proceeded from 25 January 1946 until October of that year. An estimated 1.6 million ethnic Germans were deported to the American zone of what would become West Germany. An estimated 800,000 were deported to the Soviet zone (in what would become East Germany). Several thousand died violently during the expulsion and many more died from hunger and illness as a consequence. These casualties include violent deaths and suicides, deaths in internment camps and natural causes. The joint Czech-German commission of historians stated in 1996 the following numbers: The deaths caused by violence and abnormal living conditions amount to approximately 10,000 persons killed. Another 5,000–6,000 people died of unspecified reasons related to expulsion making the total number of victims of the expulsion 15,000–16,000 (this excludes suicides, which make another approximately 3,400 cases). Approximately 225,000 Germans remained in Czechoslovakia, of whom 50,000 emigrated or were expelled soon after.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.